J&J receives CHMP positive opinion for Akeega to treat patients with metastatic hormone-sensitive prostate cancer with BRCA1/2 mutations: Beerse, Belgium Monday, February 2, 2026, ...

AMPLITUDE is the first clinical trial to evaluate potential therapies for patients with mHSPC and known HRR gene alterations, with positive results supporting the niraparib-based combination regimen ...

RRBM is associated with lower overall- and breast cancer-specific mortality among women carrying BRCA1 or BRCA2 pathogenic ...

In a study that involved more than 31,000 women who are carriers of disease-associated mutations in the BRCA1 or BRCA2 genes, researchers identified mutations that were associated with significantly ...

In this study, researchers aimed to determine whether younger BRCA1/2 carriers who undergo oophorectomy can receive menopausal hormone therapy without increasing their risk of breast cancer.

Lin WT, Beattie M, Chen LM, et al. Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non–clinic-based sample of women in northern California. Cancer. 2012 Jan 29. [Epub ahead ...

*7 pts had ≥3 CT lines. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not include a full text component.

Fast Track designation granted by U.S. FDA for evaluation of IDE161 in adult patients with HR+, Her2-, BRCA1/2 mutant advanced or metastatic breast cancer patients who have been pretreated with ...

Deescalated nab-paclitaxel plus carboplatin showed higher efficacy than nab-paclitaxel plus gemcitabine in early-stage TNBC patients. BRCA1/2 mutation carriers exhibited a more pronounced pathologic ...

More and more studies show that men face risks of cancer from BRCA1 and BRCA2 genetic mutations that are most often associated with breast and ovarian cancers in women. According to a July 25 JAMA ...